CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status
Open Access
- 16 August 2019
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-18
Abstract
Triple Negative Breast cancer (TNBC) is incurable cancer with higher rates of relapse and shorter overall survival compared with other subtypes of breast cancer. Cellular retinoic acid binding protein 2 (CRABP2) belongs to fatty acid binding protein (FABP) family which binds with all-trans retinoic acid (RA). Previous studies from the database have reported the patients with high expression of CRABP2 showed different prognosis in ER+ and ER− breast cancer. However, its biological role and exact mechanism in breast cancer remain unknown. This aim of this study was to explore how CRABP2 regulated invasion and metastasis based on the estrogen receptor-α (herein called ER) status in breast cancer. Immunohistochemical staining method was used to analyze the expression of CRABP2 in human breast cancer tissues. Lentivirus vector-based shRNA technique was used to test the functional relevance of CRABP2 knockdown in breast tumors. Tail vein injection model was used to examine the lung metastasis. Co-immunoprecipitation, Western blotting, immunofluorescence, and quantitative reverse transcription polymerase chain reaction (RT-qPCR) were conducted to investigate the underlying mechanism that influenced the ER to the regulation of CRABP2 to Lats1. We observed that knockdown of CRABP2 promotes EMT, invasion and metastasis of ER+ breast cancer cells in vitro and in vivo, whereas overexpression of CRABP2 yields the reverse results. In ER+ mammary cancer cells, the interaction of CRABP2 and Lats1 suppress the ubiquitination of Lats1 to activate Hippo pathway to inhibit the invasion and metastasis of ER+ mammary cancer. However, in ER− mammary cancer cells, the interaction of CRABP2 and Lats1 promote the ubiquitination of Lats1 to inactivate Hippo pathway to promote the invasion and metastasis of ER− mammary cancer. Our findings indicate that CRABP2 can suppress invasion and metastasis of ER+ breast cancer and promote invasion and metastasis of ER− breast cancer by regulating the stability of Lats1 in vitro and in vivo, and it provides new ideas for breast cancer therapy.Keywords
Funding Information
- Peijun Liu (81672876)
- Can Zhou (81502413)
This publication has 43 references indexed in Scilit:
- Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic MarkersCancer Research, 2012
- The different roles of ER subtypes in cancer biology and therapyNature Reviews Cancer, 2011
- ERα signaling through slug regulates E-cadherin and EMTOncogene, 2010
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 TrialJournal of Clinical Oncology, 2009
- Regulation of CRABP-II expression by MycN in Wilms tumorExperimental Cell Research, 2008
- TEAD mediates YAP-dependent gene induction and growth controlGenes & Development, 2008
- Cellular Retinoic Acid–Binding Protein II Is a Direct Transcriptional Target of MycN in NeuroblastomaCancer Research, 2006
- Down-Regulation of LATS1 and LATS2 mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast CancersClinical Cancer Research, 2005
- Ribozyme Targeting Demonstrates That the Nuclear Receptor Coactivator AIB1 Is a Rate-limiting Factor for Estrogen-dependent Growth of Human MCF-7 Breast Cancer CellsJournal of Biological Chemistry, 2001
- Expression scanning of an array of growth control genes in human tumor cell linesOncogene, 1999